On this episode of Stock Movers:
- Netflix (NFLX) shares rise after the company reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.’s studio and streaming business. The changes are designed to expedite a sale and address claims by Paramount that its cash tender offer is superior.
- Applovin (APP) shares slump underperforming tech peers after a negative research report by CapitalWatch. The stock was also weighed down by a broader tech selloff amid rising geopolitical tensions.
- Intel (INTC) share rise after the company was was upgraded to hold from reduce at HSBC, which noted that agentic artificial intelligence is driving upside to server CPU demand. Shares up 0.2% premarket.

On this episode of Stock Movers: - Netflix (NFLX) shares rise after the company reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.&rsquo;s studio and streaming business. The changes are designed to expedite a sale and address claims by Paramount that its cash tender offer is superior. - Applovin (APP) shares slump underperforming tech peers after a negative research report by CapitalWatch. The stock was also weighed down by a broader tech selloff amid rising geopolitical tensions. - Intel (INTC) share rise after the company was was upgraded to hold from reduce at HSBC, which noted that agentic artificial intelligence is driving upside to server CPU demand. Shares up 0.2% premarket.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Netflix Rises, Applovin Slumps, Intel Rises on Ratings Upgrade

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b1c07110-7486-4a1a-863e-b3d800fe6b7d/transcript

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that’s struggling to meet the surge in electricity consumption. Dominion shares rose 9.4% to $67.56 as trading closed in New York on Monday, while NextEra fell 4.6% to $89.04.


-Seagate (STX) shares fell 6.9% Monday in its worst one-day drop in nearly two months after management comments at a JPMorgan conference sparked investor fears that the company won’t be able to keep up with soaring demand for memory chips. The declines come after a blistering rally in the sector that’s spanned roughly eight weeks, boosted by solid earnings from megacap technology hyperscalers, a slew of deals for the cohort and investor enthusiasm in the risk-on trade as high demand for artificial intelligence infrastructure persists. The SOX gained nearly 60% from the start of April through a May 11 record high. 

- Regeneron Pharmaceuticals (REGN) said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues. The shares plunged in trading on Monday.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that&rsquo;s struggling to meet the surge in electricity consumption. Dominion shares rose 9.4% to $67.56 as trading closed in New York on Monday, while NextEra fell 4.6% to $89.04.
 -Seagate (STX) shares fell 6.9% Monday in its worst one-day drop in nearly two months after management comments at a JPMorgan conference sparked investor fears that the company won&rsquo;t be able to keep up with soaring demand for memory chips. The declines come after a blistering rally in the sector that&rsquo;s spanned roughly eight weeks, boosted by solid earnings from megacap technology hyperscalers, a slew of deals for the cohort and investor enthusiasm in the risk-on trade as high demand for artificial intelligence infrastructure persists. The SOX gained nearly 60% from the start of April through a May 11 record high. - Regeneron Pharmaceuticals (REGN) said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron&rsquo;s experimental drug fianlimab couldn&rsquo;t beat Merck &amp; Co.&rsquo;s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.&rsquo;s Opdualag continues. The shares plunged in trading on Monday.

NextEra Falls, Seagate Slips, Regeneron Tumbles

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/af796809-e10d-4b87-af19-b44e015c6aa6/transcript

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Seagate (STX) shares slumped as much as 8.3% after management comments at a JPMorgan conference sparked investor fears that the company won’t be able to keep up with soaring demand for memory chips. Chief Executive Officer Dave Mosley said building new factories would “take too long” and potentially set up the company with more capacity than it needs when asked during a Monday presentation whether Seagate plans to expand manufacturing capacity. 

- NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that’s struggling to meet the surge in electricity consumption. Dominion shares rose while NextEra shares fell. 

- Regeneron Pharmaceuticals (REGN) shares sank more than 10%, most intraday since May 2025, after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi and Leerink analysts downgraded their ratings on the stock following the disappointing trial update. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Seagate (STX) shares slumped as much as 8.3% after management comments at a JPMorgan conference sparked investor fears that the company won&rsquo;t be able to keep up with soaring demand for memory chips. Chief Executive Officer Dave Mosley said building new factories would &ldquo;take too long&rdquo; and potentially set up the company with more capacity than it needs when asked during a Monday presentation whether Seagate plans to expand manufacturing capacity. - NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that&rsquo;s struggling to meet the surge in electricity consumption. Dominion shares rose while NextEra shares fell. - Regeneron Pharmaceuticals (REGN) shares sank more than 10%, most intraday since May 2025, after the drugmaker&rsquo;s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi and Leerink analysts downgraded their ratings on the stock following the disappointing trial update. Regeneron&rsquo;s experimental drug fianlimab couldn&rsquo;t beat Merck &amp; Co.&rsquo;s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.&rsquo;s Opdualag continues.

Seagate Slips, NextEra Lower, Regeneron Tumbles

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/07dbfe6c-1724-4661-b7cc-b44e0139aca3/transcript

On this episode of Stock Movers:
- Dominion Energy (D) shares climb. NextEra Energy Inc. agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia.
- Regeneron (REGN US) shares sink. Regeneron Pharmaceuticals Inc. said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues. 
- Hive Digital Technologies (HIVE US) shares rise. The cryptocurrency mining firm’s cloud and data center subsidiary BUZZ HPC says it’s building a 320-megawatt AI data center in Toronto. The facility will deploy over 100,000 GPUs at full capacity, creating one of North America’s largest domestically controlled AI clusters, according to Executive Chairman Frank Holmes in a press release.

On this episode of Stock Movers: - Dominion Energy (D) shares climb. NextEra Energy Inc. agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. - Regeneron (REGN US) shares sink. Regeneron Pharmaceuticals Inc. said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron&rsquo;s experimental drug fianlimab couldn&rsquo;t beat Merck &amp; Co.&rsquo;s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.&rsquo;s Opdualag continues. - Hive Digital Technologies (HIVE US) shares rise. The cryptocurrency mining firm&rsquo;s cloud and data center subsidiary BUZZ HPC says it&rsquo;s building a 320-megawatt AI data center in Toronto. The facility will deploy over 100,000 GPUs at full capacity, creating one of North America&rsquo;s largest domestically controlled AI clusters, according to Executive Chairman Frank Holmes in a press release.

Dominion Energy Gains, Regeneron Tumbles, Hive Digital Technologies Rises as Subsidiary Plans High-Capacity Data Center

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/51f9d15a-58f0-4c13-abfa-b44e00faf04a/transcript

Netflix Rises, Applovin Slumps, Intel Rises on Ratings Upgrade

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips